Similar articles

• Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.

  Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Kaul S, et al. Circulation. 2010 Apr 27;121(16):1868-77. doi: 10.1161/CIR.0b013e3181d34114. Epub 2010 Feb 23. Circulation. 2010. PMID: 20179252 No abstract available.
• Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.

  Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH; American Heart Association; American College Of Cardiology Foundation. Kaul S, et al. J Am Coll Cardiol. 2010 Apr 27;55(17):1885-94. doi: 10.1016/j.jacc.2010.02.014. J Am Coll Cardiol. 2010. PMID: 20413044 No abstract available.
• [The effects of thiazolidinedione from the cardiologic viewpoint].

  Ziegler R. Ziegler R. Med Monatsschr Pharm. 2005 Oct;28(10):365. Med Monatsschr Pharm. 2005. PMID: 16245456 German. No abstract available.
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association; American Diabetes Association. Nesto RW, et al. Circulation. 2003 Dec 9;108(23):2941-8. doi: 10.1161/01.CIR.0000103683.99399.7E. Circulation. 2003. PMID: 14662691 Review. No abstract available.
• Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.

  Mitka M. Mitka M. JAMA. 2013 Jul 17;310(3):246-7. doi: 10.1001/jama.2013.8141. JAMA. 2013. PMID: 23860970 No abstract available.